業 績 一 覧 2021

原著

1. Morimoto H, Hida Y, Maishi N, Nishihara H, Hatanaka Y, Li C, Matsuno Y, Nakamura T, Hirano S, Hida K. Biglycan, tumor endothelial cell secreting proteoglycan, as possible biomarker for lung cancer. Thorac Cancer. 2021 May;12(9):1347-1357.
2. Nakamura K, Aimono E, Oba J, Hayashi H, Tanishima S, Hayashida T, Chiyoda T, Kosaka T, Hishida T, Kawakubo H, Kitago M, Okabayashi K, Funakoshi T, Okita H, Ikeda S, Takaishi H, Nishihara H. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status. Med Oncol. 2021 Mar; 12;38(4):36.
3. Yokouchi H, Nishihara H, Harada T, Amano T, Ohkuri T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Higuchi M, Honjo O, Minami Y, Watanabe N, Nishimura M, Suzuki H, Dosaka-Akita H, Isobe H Prognostic significance of OX40+ lymphocytes in tumor stroma of surgically resected small-cell lung cancer Oncoimmunology. 2021 Sep; 18;10(1):1971430.
4. Narahira A, Kitamura S, Maeda T, Nishihara H, Yanagi T Multiple squamous cell carcinomas arising on an epidermal nevus harboring HRAS p.G13R mutation. The Journal of dermatology 2021 Feb;48(2):e92-e93.
5. Sunami K, Naito Y, Aimono E, Amano T, Ennishi D, Kage H, Kanai M, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Kohsaka S, Tsuchihara K, Yoshino T. The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan. Int J Clin Oncol. 2021 Mar;26(3):443-449.
6. Takagi H, Zhao S, Muto S, Yokouchi H, Nishihara H, Harada T, Yamaguchi H, Mine H, Watanabe M, Ozaki Y, Inoue T, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Kanno R, Aoki M, Chengbo Tan, Shimoyama S, Yamazaki S, Kikuchi H, Sakakibara-Konishi J, Oizumi S, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Honjo O, Minami Y, Nishimura M, Dosaka-Akita H, Nakamura K, Inano A, Isobe H, Suzuki H Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004) Lung Cancer. 2021 Mar;153:134-142.
7. Shimozaki K, Hirata K, Horie S, Chida A, Tsugaru K, Hayashi Y, Kawasaki K, Miyanaga R, Hayashi H, Mizuno R, Funakoshi T, Hosoe N, Hamamoto Y, Kanai T. The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study. Diagnostics (Basel). 2021 Mar; 18;11(3):543.
8. Iwasaki E, Fukuhara S, Horibe M, Kawasaki S, Seino T, Takimoto Y, Tamagawa H, Machida Y, Kayashima A, Noda M, Hayashi H, Kanai T. Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment. Diagnostics (Basel). 2021 Mar; 8;11(3):469.
9. Hagio K, Amano T, Hayashi H, Takeshita T, Oshino T, Kikuchi J, Ohhara Y, Yabe I, Kinoshita I, Nishihara H, Yamashita H.: Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor‑positive, HER2‑negative metastatic breast cancer. Sci Rep. 2021 Apr; 14;11(1):8109.
10. Oba J, Taniguchi H, Sato M, Takamatsu R, Morikawa S, Nakagawa T, Takaishi H, Saya H, Matsuo K, Nishihara H. RT-PCR Screening Tests for SARS-CoV-2 with Saliva Samples in Asymptomatic People: Strategy to Maintain Social and Economic Activities while Reducing the Risk of Spreading the Virus. Keio J Med. 2021 Jun; 25;70(2):35-43.
11. Haraguchi R, Hoshi H, Ichikawa S, Hanyu M, Nakamura K, Fukasawa K, Poza J, Rodríguez-González V, Gómez C, Shigihara Y. The Menstrual Cycle Alters Resting-State Cortical Activity: A Magnetoencephalography Study. Front Hum Neurosci. 2021 Jul; 26:15:652789.
12. Ueki A, Sugano K, Misu K, Aimono E, Nakamura K, Tanishima S, Tanaka N, Mikami S, Hirasawa A, Ando M, Yoshida T, Oya M, Nishihara H, Kosaki K. Germline Whole-Gene Deletion of FH Diagnosed from Tumor Profiling. International journal of molecular sciences 2021 Jul; 26;22(15):7962.
13. Shimozaki K, Sukawa Y, Sato Y, Horie S, Chida A, Tsugaru K, Togasaki K, Kawasaki K, Hirata K, Hayashi H, Hamamoto Y, Kanai T. Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. Future Oncol. 2021 Jul;17(20):2593-2603.
14. Taniguchi H, Natori Y, Miyagi Y, Hayashi K, Nagamura F, Kataoka K, Imai K. Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex. Int J Cancer. 2021 Aug; 1;149(3):646-656.
15. Miyamoto S, Suda G, Ishikawa M, Hayashi H, Nimura S, Matsuno Y, Mori R, Tanishima S, Kudo T, Takagi T, Yamamoto Y, Ono S, Shimizu Y, Sakamoto N. Genomic Profiling of Small Superficial Non-Ampullary Duodenal Epithelial Tumors. JGH Open. 2021 Aug; 3;5(9):1071-1077.
16. Kuroda Y, Chiyoda T, Kawaida M, Nakamura K, Aimono E, Yoshimura T, Takahashi M, Saotome K, Yoshihama T, Iwasa N, Sakai K, Yamagami W, Nishihara H, Aoki D. ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer. Gynecologic oncology 2021 Sep;162(3):679-685.
17. Takamatsu K, Tanaka N, Hakozaki K, Takahashi R, Teranishi Y, Murakami T, Kufukihara R, Niwa N, Mikami S, Shinojima T, Sasaki T, Sato Y, Kume H, Ogawa S, Kakimi K, Kamatani T, Miya F, Tsunoda T, Aimono E, Nishihara H, Sawada K, Imamura T, Mizuno R, Oya M. Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. Nature communications 2021 Sep; 20;12(1):5547.
18. Yamaguchi S, Hirata K, Okamoto M, Shimosegawa E, Hatazawa J, Hirayama R, Kagawa N, Kishima H, Oriuchi N, Fujii M, Kobayashi K, Kobayashi H, Terasaka S, Ken-ichi Nishijima, Kuge Y, Yoichi M Ito, Nishihara H, Tamaki N, Shiga T. Determination of Brain Tumor Recurrence using ¹¹ C‐methionine Positron Emission Tomography after Radiotherapy Cancer Science 2021 Oct;112(10):4246-4256.
19. Kawamoto Y, Nakatsumi H, Harada K, Muranaka T, Ishiguro A, Kobayashi Y, Hayashi H, Yuki S, Sawada K, Yagisawa M, Nakano S, Sakamoto N, Komatsu Y. A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). Oncologist. 2021 Oct;26(10):e1675-e1682.
20. Shimozaki K, Hayashi H, Tanishima S, Horie S, Chida A, Tsugaru K, Togasaki K, Kawasaki K, Aimono E, Hirata K, Nishihara H, Kanai T, Hamamoto Y. Concordance Analysis of Microsatellite Instability Status between Polymerase Chain Reaction based Testing and Next Generation Sequencing for Solid Tumors. Sci Rep. 2021 Oct 8;11(1):20003.
21. Hakozaki K, Tanaka N, Takamatsu K, Takahashi R, Yasumizu Y, Mikami S, Shinojima T, Kakimi K, Kamatani T, Miya F, Tsunoda T, Aimono E, Nishihara H, Mizuno R, Oya M. Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma. British journal of cancer 2021 Nov;125(11):1533-1543.

症例報告

1. Nakamura K, Aimono E, Takamatsu R, Tanishima S, Tohyama T, Sasano K, Sakuma H, Nishihara H. Genetic Profiling of Malignant Melanoma Arising from an Ovarian Mature Cystic Teratoma: A Case Report. Int J Mol Sci. 2021 Feb; 28;22(5):2436.
2. Ono H, Kusano M, Yokoyama H, Yoshida H, Fukushima H, Kawakami M, Okamura M, Aoki T, Asakage N, Nagashima K, Danjo Y, Hayashi H, Nishihara H, Shimizu Y, Shimamura T. Endoscopic Identification of Colorectal Cancer Margin by Indocyanine Green Fluorescence Imaging. Journal of GHR 2021 Feb;10(1):3445-3451.
3. Ono H, Yokoyama H, Yoshida H, Fukushima H, Kawakami M, Okamura M, Aoki T, Asakage N, Danjo Y, Nagashima K, Hayashi H, Nishihara H, Shimizu Y, Shimamura T, Kusano M. Adenocarcinoma of the Third Portion of the Duodenum with an Acute Cholecystitis. Journal of GHR 2021 Feb;10(1):3452-3455.
4. Ono H, Yokoyama H, Yoshida H, Fukushima H, Kawakami M, Okamura M, Aoki T, Asakage N, Danjo Y, Nagashima K, Hayashi H, Nishihara H, Shimizu Y, Shimamura T, Kusano M. Actinomycosis of an Appendix with a Cecal Abscess. Journal of GHR 2021 Apr;10(2):3488-3491.
5. Shojo K, Kosaka T, Nakamura K, Hongo H, Kobayashi H, Mikami S, Nishihara H, Oya M. First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion. IJU case reports 2021 Mar; 17;4(3):176-179.
6. Daimon T, Kosaka T, Hongo H, Aimono E, Nakamura K, Mikami S, Nishihara H, Oya M. Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification. IJU case reports 2021 May; 5;4(4):216-219.
7. Matsumoto K, Kosaka T, Nakamura K, Nishihara H, Oya M. A first Japanese case of BRCA2 and RB1 co-loss organ-confined prostate cancer successfully treated by radical prostatectomy. International cancer conference journal 2021 Mar; 27;10(3):170-173.
8. Matsumoto H, Takamatsu R, Abe N, Unesoko M, Zaha H, Ishii A, Nakada N, Nishihara H, Tan PH, Yoshimi N. Spiradenoma of the breast: a rare diagnostic pitfall in the evaluation of solid-basaloid breast lesions with a dual cell population. Virchows Arch. 2021 Aug;479(2):401-405.
9. Kobayashi H, Kosaka T, Nakamura K, Shojo K, Hongo H, Mikami S, Nishihara H, Oya M. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations. BMC medical genomics 2021 Oct; 9;14(1):245.
10. Omura M, Kosaka T, Aimono E, Nakamura K, Hongo H, Mikami S, Nishihara H, Oya M. First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations. IJU case reports 2021 Oct; 20;5(1):41-44.
11. Ono H, Kusano M, Yokoyama H, Yoshida H, Fukushima H, Kawakami M, Okamura M, Aoki T, Asakage N, Nagashima K, Danjo Y, Hayashi H, Nishihara H, Shimizu Y, Shimamura T. Effectiveness of Indocyanine Green Fluorescence in Gastric Adenosquamous Carcinoma with Hepatic Metastases. Journal of GHR 2021;10(3):3531-3536. 2021 Oct; 20;5(1):41-44.